Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Oxford Immunotec Global PLC    OXFD   GB00BGFBB958

OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/12/2018 09/13/2018 09/14/2018 09/17/2018 09/18/2018 Date
15.75(c) 15.62(c) 15.63(c) 15.49(c) 15.87(c) Last
120 226 37 652 66 143 61 805 160 831 Volume
+1.61% -0.83% +0.06% -0.90% +2.45% Change
More quotes
Financials (USD)
Sales 2018 113 M
EBIT 2018 -20,4 M
Net income 2018 -24,8 M
Finance 2018 35,6 M
Yield 2018 -
Sales 2019 128 M
EBIT 2019 -14,3 M
Net income 2019 -17,7 M
Finance 2019 34,5 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 3,33x
EV / Sales2019 2,96x
Capitalization 412 M
More Financials
Company
Oxford Immunotec Global Plc operates as a medical diagnostics company, which develops and commercializes proprietary tests for under-served immune-regulated conditions.Its current product lines and development activities principally focus on four areas: infectious diseases, transplantation,... 
More about the company
Surperformance© ratings of Oxford Immunotec Global PL
Trading Rating : Investor Rating :
More Ratings
Latest news on OXFORD IMMUNOTEC GLOBAL PL
07/31OXFORD IMMUNOTEC GLOBAL PLC : to Host Earnings Call
AC
05/29Oxford Immunotec to Present at the Jefferies 2018 Healthcare Conference
GL
05/22Oxford Immunotec Announces Launch of the Accutix™ Brand
GL
05/01OXFORD IMMUNOTEC GLOBAL PLC : to Host Earnings Call
AC
03/01Oxford Immunotec Announces Appointment of Mark Klausner to the Board of Direc..
GL
02/27OXFORD IMMUNOTEC GLOBAL PLC : to Host Earnings Call
AC
01/08Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Ye..
GL
01/03Oxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare Confere..
GL
2017QIAGEN : and Oxford Immunotec Settle Patent Infringement Lawsuit
PR
2017Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit
GL
More news
Sector news : Medical Diagnostic & Testing Equipment
09/18Exclusive - India, U.S. closing in on package deal to remove trade irritants
RE
09/07THERMO FISHER SCIENTIFIC : to Buy Becton Dickinson's Advanced Bioprocessing Unit..
DJ
09/07THERMO FISHER SCIENTIFIC : to Buy Becton Dickinson's Advanced Bioprocessing Unit
DJ
08/22Shares in hearing aid group GN Store Nord rise after outlook lift
RE
08/14AGILENT TECHNOLOGIES : Profit Beats Expectations, Guidance in Line With Wall Str..
DJ
More sector news : Medical Diagnostic & Testing Equipment
Latest Tweets
09/17Oxford Immunotec Global $OXFD versus IDEXX Laboratories $IDXX Head to Head Co.. 
09/13Get the latest news and updates for $ARMK $VNCE $WBAI $RYB $OXFD automaticall.. 
09/13Oxford Immunotec Global $OXFD Upgraded to Buy at ValuEngine  
09/12Oxford Immunotec Global $OXFD Upgraded to Sell at BidaskClub  
09/12ValuEngine Upgrades Oxford Immunotec Global $OXFD to Buy  
More tweets
Qtime:14
News from SeekingAlpha
08/02YOUR DAILY PHARMA SCOOP : Puma Progresses, Kala In Phase 3, Teva Fails 
07/31Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q2 2018 Result.. 
07/31Oxford Immunotec launches T-Cell Select in Europe and ROW countries 
07/31Oxford Immunotec Global EPS in-line, beats on revenue 
05/01Oxford Immunotec Global PLC 2018 Q1 - Results - Earnings Call Slides 
Chart OXFORD IMMUNOTEC GLOBAL PLC
Duration : Period :
Oxford Immunotec Global PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXFORD IMMUNOTEC GLOBAL PL
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 16,8 $
Spread / Average Target 5,9%
EPS Revisions
Managers
NameTitle
Peter James Wrighton-Smith Chief Executive Officer & Executive Director
Richard Alvin Sandberg Chairman
Stefan C. Linn Chief Operating Officer
Richard M. Altieri Chief Financial & Accounting Officer
Richard J. Wenstrup Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD IMMUNOTEC GLOBAL PLC13.60%402
SARTORIUS AG82.31%12 442
MYRIAD GENETICS, INC.34.95%3 287
VAREX IMAGING CORP-24.92%1 140
DIRUI INDUSTRIAL CO LTD--.--%684
NH SPECIAL PURPOSE ACQTN 2ND CO LTD--.--%320